Literature DB >> 17942237

Protracted effects of chronic oral haloperidol and risperidone on nerve growth factor, cholinergic neurons, and spatial reference learning in rats.

A V Terry1, D A Gearhart, S Warner, E J Hohnadel, M-L Middlemore, G Zhang, M G Bartlett, S P Mahadik.   

Abstract

The primary therapeutic agents used for schizophrenia, antipsychotic drugs, ameliorate psychotic symptoms; however, their chronic effects on cognition (or the physiologic processes of the brain that support cognition) are largely unknown. The purpose of this rodent study was to extend our previous work on this subject by investigating persistent effects (i.e. during a 14 day drug-free washout period) of chronic treatment (i.e. ranging from 45 days to 6 months) with a representative first and second generation antipsychotic. Drug effects on learning and memory and important neurobiological substrates of memory, the neurotrophin, nerve growth factor (NGF) and its receptors, and certain components of the basal forebrain cholinergic system were investigated. Behavioral effects of oral haloperidol (2.0 mg/kg/day), or risperidone (2.5 mg/kg/day) were assessed in an open field, a water maze task, and a radial arm maze procedure and neurochemical effects in brain tissue were subsequently measured by enzyme-linked immunosorbent assays (ELISAs). The results indicated that both antipsychotics produced time-dependent and protracted deficits in the performance of a water maze procedure when compared with vehicle-treated controls, while neither drug was associated with significant alterations in radial arm maze performance. Interestingly, haloperidol, but not risperidone, was detectible in the rodent brain in appreciable levels for up to 2 weeks after drug discontinuation. Both antipsychotics were also associated with reduced levels of NGF protein in the basal forebrain and prefrontal cortex and significant (or nearly significant) decreases in phosphorylated tropomyosin-receptor kinase A (TrkA) protein and the vesicular acetylcholine transporter (depending on the brain region analyzed). Neither antipsychotic markedly affected TrkA or p75 neurotrophin receptor levels. These data in rats indicate that chronic treatment with either haloperidol or risperidone may be associated with protracted negative effects on cognitive function as well as important neurotrophin and neurotransmitter pathways that support cognition.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942237      PMCID: PMC2200296          DOI: 10.1016/j.neuroscience.2007.09.014

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  50 in total

1.  Comparison of rat dopamine D2 receptor occupancy for a series of antipsychotic drugs measured using radiolabeled or nonlabeled raclopride tracer.

Authors:  Vanessa N Barth; Eyassu Chernet; Laura J Martin; Anne B Need; Karen S Rash; Michelle Morin; Lee A Phebus
Journal:  Life Sci       Date:  2006-01-24       Impact factor: 5.037

2.  Spatial memory and hippocampal function.

Authors:  D S Olton; B C Papas
Journal:  Neuropsychologia       Date:  1979       Impact factor: 3.139

Review 3.  Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses.

Authors:  R J Baldessarini; B M Cohen; M H Teicher
Journal:  Arch Gen Psychiatry       Date:  1988-01

Review 4.  Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism.

Authors:  Alvin V Terry; Sahebarao P Mahadik
Journal:  J Pharmacol Exp Ther       Date:  2006-09-11       Impact factor: 4.030

5.  Oral haloperidol or risperidone treatment in rats: temporal effects on nerve growth factor receptors, cholinergic neurons, and memory performance.

Authors:  A V Terry; D A Gearhart; S E Warner; G Zhang; M G Bartlett; M-L Middlemore; W D Beck; S P Mahadik; J L Waller
Journal:  Neuroscience       Date:  2007-04-16       Impact factor: 3.590

6.  Time-dependent effects of haloperidol and ziprasidone on nerve growth factor, cholinergic neurons, and spatial learning in rats.

Authors:  Alvin V Terry; Vinay Parikh; Debra A Gearhart; Anilkumar Pillai; Elizabeth Hohnadel; Samantha Warner; Henry A Nasrallah; Sahebarao P Mahadik
Journal:  J Pharmacol Exp Ther       Date:  2006-05-15       Impact factor: 4.030

7.  Liquid chromatography/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat plasma.

Authors:  Guodong Zhang; Alvin V Terry; Michael G Bartlett
Journal:  Rapid Commun Mass Spectrom       Date:  2007       Impact factor: 2.419

8.  Decreased encoding efficiency in schizophrenia.

Authors:  Tara A Cairo; Todd S Woodward; Elton T C Ngan
Journal:  Biol Psychiatry       Date:  2005-10-17       Impact factor: 13.382

9.  Adverse effects of risperidone on spatial working memory in first-episode schizophrenia.

Authors:  James L Reilly; Margret S H Harris; Matcheri S Keshavan; John A Sweeney
Journal:  Arch Gen Psychiatry       Date:  2006-11

10.  Chronic haloperidol effects on oral movements and radial-arm maze performance in rats.

Authors:  E D Levin; D M Galen; G D Ellison
Journal:  Pharmacol Biochem Behav       Date:  1987-01       Impact factor: 3.533

View more
  13 in total

1.  Differential long-term effects of haloperidol and risperidone on the acquisition and performance of tasks of spatial working and short-term memory and sustained attention in rats.

Authors:  Elizabeth J Hutchings; Jennifer L Waller; Alvin V Terry
Journal:  J Pharmacol Exp Ther       Date:  2013-09-16       Impact factor: 4.030

2.  Negative effects of chronic oral chlorpromazine and olanzapine treatment on the performance of tasks designed to assess spatial learning and working memory in rats.

Authors:  A V Terry; S E Warner; L Vandenhuerk; A Pillai; S P Mahadik; G Zhang; M G Bartlett
Journal:  Neuroscience       Date:  2008-08-27       Impact factor: 3.590

3.  The cannabinergic system is implicated in the upregulation of central NGF protein by psychotropic drugs.

Authors:  Parichehr Hassanzadeh; Sina Rahimpour
Journal:  Psychopharmacology (Berl)       Date:  2010-12-18       Impact factor: 4.530

4.  No Dopamine Agonist Modulation of Brain [18F]FEOBV Binding in Parkinson's Disease.

Authors:  Roger L Albin; Prabesh Kanel; Teus van Laar; Sygrid van der Zee; Stiven Roytman; Robert A Koeppe; Peter J H Scott; Nicolaas I Bohnen
Journal:  Mol Pharm       Date:  2022-03-15       Impact factor: 4.939

Review 5.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia.

Authors:  Jared W Young; Susan B Powell; Victoria Risbrough; Hugh M Marston; Mark A Geyer
Journal:  Pharmacol Ther       Date:  2009-03-06       Impact factor: 12.310

6.  Effects of omega-3 essential fatty acids (omega-3 EFAs) on motor disorders and memory dysfunction typical neuroleptic-induced: behavioral and biochemical parameter.

Authors:  Raquel Cristine Silva Barcelos; Dalila Moter Benvegnú; Nardeli Boufleur; Patrícia Reckziegel; Liz Girardi Müller; Camila Pase; Tatiana Emanuelli; Marilise Escobar Bürger
Journal:  Neurotox Res       Date:  2009-07-31       Impact factor: 3.911

Review 7.  Effects of Antipsychotic Drugs: Cross Talk Between the Nervous and Innate Immune System.

Authors:  Ayushi Anna Dinesh; Juned Islam; Javad Khan; Federico Turkheimer; Anthony C Vernon
Journal:  CNS Drugs       Date:  2020-09-25       Impact factor: 5.749

8.  Comparative analysis of the neurovascular injury and functional outcomes in experimental stroke models in diabetic Goto-Kakizaki rats.

Authors:  Weiguo Li; Zhi Qu; Roshini Prakash; Connie Chung; Handong Ma; Md Nasrul Hoda; Susan C Fagan; Adviye Ergul
Journal:  Brain Res       Date:  2013-10-19       Impact factor: 3.252

Review 9.  Effects of antipsychotics on dentate gyrus stem cell proliferation and survival in animal models: a critical update.

Authors:  Gerburg Keilhoff; Paolo Fusar-Poli; Axel Becker
Journal:  Neural Plast       Date:  2012-10-24       Impact factor: 3.599

10.  Role of the central cholinergic system in the therapeutics of schizophrenia.

Authors:  Alvin V Terry
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.